載入中
Fee-Charging Standards for the Review of Drug Advertisements
1.中華民國九十二年十二月十二日行政院衛生署衛署藥字第 0920332903 號令訂定發布全文 5 條；並自九十三年一月一日施行 2.中華民國九十三年七月二十九日行政院衛生署衛署藥字第 0930317278 號令修正發布名稱及全文 4 條；本標準修正條文自發布日施行 （原名稱：藥物及化粧品廣告申請案件收費標準；新名稱：藥物及化粧 品廣告審查費收費標準） 3.中華民國一百零四年四月七日衛生福利部部授食字第 1041600943 號令 修正發布全文 4 條；並自一百零四年七月一日施行 4.中華民國一百零九年八月七日衛生福利部衛授食字第 1091407515 號令 修正發布名稱及全文 4 條；並自一百十年一月一日施行 （原名稱：藥物及化粧品廣告審查費收費標準；新名稱：藥品廣告審查 費收費標準） 5.中華民國一百十三年五月十七日衛生福利部衛授食字第 1131404615 號 令修正發布全文 4 條；並自發布日施行
資料來源：全國法規資料庫（ChOrder.json，版本 2026/7/24 上午 12:00:00）・政府資料開放授權
These Standards are adopted pursuant to the provisions of Article 7 and Article 10 of the Charges and Fees Act.
These Standards are applicable to drug advertisements that apply for review in accordance with the regulations of the Pharmaceutical Affairs Act.
1The standards for charging fees to review drug advertisements are as follows：
2I. The review fee charged for new applications of advertisement shall be NT$6,000 per application.
3II. The review fee charged for applications of extension shall be NT$2,200 per application.
4III. For reissuing approved forms that have been lost, NT$1,700 shall be charged per application.
5IV. The review fee charged for letter of inquiry about drug advertisement regulations shall be NT$2,800 per application.
6V. The review fee charged for letter of inquiry about health and disease education advertisement shall be NT$6,000 per application.
These Standards shall be implemented from the date of promulgation.